Company Focus
BioNTech
Related News
Insights
Company Spotlight
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology company focused on creating and developing engineered IgM antibodies.
Latest News & Features of interest to BioNTech
Biotechnology
US pharma major Merck & Co has secured a key endorsement for its newly approved respiratory syncytial virus (RSV) prevention product, Enflonsia (clesrovimab), as a majority of an influential advisory panel voted to recommend its use in newborns ahead of the 2025-2026 RSV season. 27 June 2025
Biotechnology
The US Food and Drug Administration (FDA) has required and approved updates to the Prescribing Information for Comirnaty (COVID-19 Vaccine, mRNA) manufactured by Pfizer and Spikevax (COVID-19 Vaccine, mRNA) manufactured Moderna to include new safety information about the risks of myocarditis and pericarditis following administration of mRNA COVID-19 vaccines. 26 June 2025
Pharmaceutical
Republican Senator Bill Cassidy has called for Wednesday’s meeting of the Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) to be delayed. 25 June 2025
Pharmaceutical
Health and Human Services Secretary Robert F Kennedy Jr came under heavy scrutiny from Democratic lawmakers during a heated budget hearing on Capitol Hill, as concerns mounted over his handling of vaccine policy, sweeping agency cuts, and what some members described as a disregard for transparency and scientific integrity. 25 June 2025
Pharmaceutical
Last week the US Food and Drug Administration approved Gilead Sciences Yeztugo (lenacapavir) for the prevention of HIV infection, making the first and only FDA approved HIV pre-exposure prophylaxis (PrEP) option offering six months of protection. 25 June 2025
Biotechnology
AI precision-medicine company Sonrai Analytics and German biotech Plectonic Biotech have entered a partnership to accelerate the development of next-generation immunotherapies using Plectonic’s LOGIBODY platform. 24 June 2025
Pharmaceutical
Cidara Therapeutics, a US biotech leveraging its Cloudbreak platform for next‑generation antivirals, saw its stock more than double after announcing positive Phase IIb NAVIGATE results for its once‑per‑season influenza prevention therapy, CD388. 24 June 2025
Pharmaceutical
US pharma giant Merck & Co today announced positive top-line results from the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. 23 June 2025
Pharmaceutical
Armed with an asset that could be an improvement on Pfizer’s blockbuster smoking cessation drug Chantix/Champix (varenicline), Achieve Life Sciences (Nasdaq: ACHV) has confidence in its prospects of addressing the global smoking health and nicotine addiction epidemic. 23 June 2025
Pharmaceutical
US healthcare group Abbott has signed a wide-ranging agreement with health authorities in Abu Dhabi to localize pharmaceutical manufacturing, develop biosimilars, and accelerate digital transformation, as the emirate deepens its bid to become a regional powerhouse in the global life sciences sector. 20 June 2025
Latest In Brief for BioNTech
Biotechnology
Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics. 3 July 2025
Latest Relevant Ones To Watch News
Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a privately-held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. 4 July 2025
12 June 2025
24 March 2025
11 March 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze